https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-06-18 / Cancer Cell Int. 2018;18:85
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-06-18 / Cancer Cell Int. 2018;18:852018-06-18 00:00:002019-02-15 08:46:17Targeting dendritic cells in pancreatic ductal adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-04-01 / Anticancer Res. 2018 04;38(4):2217-2225
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-04-01 / Anticancer Res. 2018 04;38(4):2217-22252018-04-01 00:00:002019-02-15 08:52:40WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-25 / Integr Cancer Ther 2018 09;17(3):994-999
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-25 / Integr Cancer Ther 2018 09;17(3):994-9992018-02-25 00:00:002018-02-25 00:00:00Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-01 / Ann. Oncol. 2017 Dec;28(12):2950-2961
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-01 / Ann. Oncol. 2017 Dec;28(12):2950-29612017-12-01 00:00:002017-12-01 00:00:00Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-23 / Int J Hyperthermia 2018 11;34(7):969-979
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-23 / Int J Hyperthermia 2018 11;34(7):969-9792017-11-23 00:00:002019-03-27 11:17:45The clinical benefit of hyperthermia in pancreatic cancer: a systematic review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-10-01 / Am J Cancer Res 2017;7(10):2091-2102
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-10-01 / Am J Cancer Res 2017;7(10):2091-21022017-10-01 00:00:002019-02-15 08:47:56Dendritic cells based immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-2516
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-09-13 / Int. J. Cancer 2017 12;141(12):2505-25162017-09-13 00:00:002017-09-13 00:00:00Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-07-25 / J Glob Oncol 2018 Sep;4:1-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-07-25 / J Glob Oncol 2018 Sep;4:1-42017-07-25 00:00:002017-07-25 00:00:00Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-03 / J Clin Oncol 35, 2017 (suppl; abstr TPS4153)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-03 / J Clin Oncol 35, 2017 (suppl; abstr TPS4153)2017-06-03 00:00:002017-06-03 00:00:00A phase III, double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-05-17 / Cell J 2017;19(Suppl 1):86-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-05-17 / Cell J 2017;19(Suppl 1):86-952017-05-17 00:00:002017-05-17 00:00:00The Role of Radiofrequency Hyperthermia in The Radiosensitization of A Human Prostate Cancer Cell Line
